| Anacetrapib | cardiovascular prevention, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Coronary revascularization | no data | | Carotid revascularization | no data | | cardiovascular events including revascularization | 0.83 [0.44 1.58] | p=1.00 | 0 | 1928 | 2 | DEFINE, REALIZE, | | cardiovascular events | 0.76 [0.40 1.47] | p=1.00 | 0 | 1623 | 1 | DEFINE, | | Cardiovascular death | 4.00 [0.45 35.91] | p=1.00 | 0 | 1623 | 1 | DEFINE, | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death | no data | | Non fatal MI | 0.67 [0.24 1.88] | p=1.00 | 0 | 1623 | 1 | DEFINE, | | All cause death | 1.38 [0.55 3.44] | p=1.00 | 0 | 1623 | 1 | DEFINE, | | Non fatal stroke | 1.00 [0.29 3.47] | p=1.00 | 0 | 1623 | 1 | DEFINE, |
| Trial | Studied treatment | Control | Patients |
|---|
| DEFINE, 2010 | anacetrapib 100mg fr 18 months | placebo | patients with coronary heart disease or at high risk for coronary heart disease | | REALIZE, 2015 | oral anacetrapib 100 mg for 52 weeks | placebo | patients aged 18-80 years with a genotype-confirmed or clinical diagnosis of heterozygous familial hypercholesterolaemia, on optimum lipid-lowering treatment for at least 6 weeks, and with an LDL-C concentration of 2·59 mmol/L or higher without cardiovascular disease or 1·81 mmol/L or higher with cardiovascular disease |
| |
| Torcetrapib | cardiovascular prevention, in all type of patients | vs placebo | Coronary revascularization by 25% suggested All cause death by 53% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Coronary revascularization | 1.25 [1.10 1.41] | p=0.04 | 0 | 16255 | 2 | ILLUMINATE, ILLUSTRATE, | | Carotid revascularization | no data | | cardiovascular events including revascularization | no data | | cardiovascular events | 1.16 [0.95 1.41] | p=1.00 | 0 | 15067 | 1 | ILLUMINATE, | | Cardiovascular death | 1.36 [0.89 2.10] | p=1.00 | 0 | 15971 | 2 | RADIANCE 1, ILLUMINATE, | | stroke (fatal and non fatal) | 0.97 [0.64 1.47] | p=1.00 | 0 | 16255 | 2 | ILLUMINATE, ILLUSTRATE, | | Coronary event | 1.22 [0.98 1.52] | p=1.00 | 0 | 15067 | 1 | ILLUMINATE, | | Coronary death | 1.21 [0.76 1.90] | p=1.00 | 0 | 16255 | 2 | ILLUMINATE, ILLUSTRATE, | | Non fatal MI | 1.17 [0.93 1.48] | p=1.00 | 0 | 17159 | 3 | RADIANCE 1, ILLUMINATE, ILLUSTRATE, | | All cause death | 1.53 [1.12 2.09] | p=0.04 | 0 | 17159 | 3 | RADIANCE 1, ILLUMINATE, ILLUSTRATE, | | Non fatal stroke | 1.01 [0.06 16.18] | p=1.00 | 0 | 904 | 1 | RADIANCE 1, |
| Trial | Studied treatment | Control | Patients |
|---|
| RADIANCE 1, 2007 | atorvastatin combined with 60 mg of torcetrapib | atorvastatin monotherapy | patients with heterozygous familial hypercholesterolemia | | ILLUMINATE, 2007 | torcetrapib 60mg daily plus atorvastatin (at a dose established during the runinperiod) | atorvastatin alone | patients at highcardiovascular risk | | RADIANCE 2, 2007 | torcetrapib 60mg daily (on top of atorvastatin attitrated dose) | placebo +atorvastatin attitrated dose | patients with mixed dyslipidaemia | | ILLUSTRATE, 2007 | atorvastatin plus 60 mg of torcetrapib daily | atorvastatin monotherapy | patients with coronary disease |
| |
| Bezafibrate | cardiovascular prevention, in all type of patients | vs placebo | Coronary event by 16% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.94 [0.73 1.21] | p=1.00 | 0 | 1568 | 1 | LEADER, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.93 [0.67 1.29] | p=1.00 | 0 | 3090 | 1 | BIP, | | Coronary event | 0.84 [0.71 0.99] | p=0.04 | 0 | 4903 | 4 | BECAIT, BIP, SENDCAP, LEADER, | | Coronary death and non fatal MI | 0.91 [0.74 1.11] | p=1.00 | 0 | 3090 | 1 | BIP, | | Coronary death | 1.03 [0.72 1.48] | p=1.00 | 0 | 3182 | 2 | BECAIT, BIP, | | cardiac death | 1.04 [0.84 1.29] | p=1.00 | 0 | 4914 | 4 | BECAIT, BIP, SENDCAP, LEADER, | | MACE | 0.92 [0.79 1.06] | p=1.00 | 0 | 3182 | 2 | BECAIT, BIP, | | Non fatal MI | 0.87 [0.69 1.09] | p=1.00 | 0 | 3090 | 1 | BIP, | | All cause death | 1.05 [0.90 1.24] | p=1.00 | 0 | 4914 | 4 | BECAIT, BIP, SENDCAP, LEADER, | | non cardiovascular death | 1.03 [0.72 1.46] | p=1.00 | 0 | 3182 | 2 | BECAIT, BIP, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | 0.57 [0.13 2.56] | p=1.00 | 0 | 92 | 1 | BECAIT, | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| BECAIT, 1996 | bezafibrate 200 mg three times daily | placebo | dyslipidaemic male survivors of myocardial infarction who were younger than 45 years at the time of the event | | BIP, 2000 | bezafibrate 400 mg/d | placebo | patients with a previous myocardial infarction or stable angina, total cholesterol of 180 to 250 mg/dL, HDL-C < or =45 mg/dL, triglycerides < or =300 mg/dL, and low-density lipoprotein cholesterol < or =180 mg/dL | | SENDCAP, 1998 | bezafibrate 400 mg daily | placebo | type 2 diabetic subjects without a history of clinical cardiovascular | | LEADER, 2002 | bezafibrate 400 mg daily | placebo | men with lower extremity arterial disease |
| |
| Clofibrate | cardiovascular prevention, in all type of patients | vs placebo | Venous thromboembolism by 78% suggested Coronary event by 13% suggested Coronary death by 14% suggested Non fatal MI by 18% suggested non cardiovascular death by 42% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Venous thromboembolism | 1.78 [1.07 2.95] | p=0.04 | 0 | 3892 | 1 | CDP Clofibrate, | | cardiovascular events | 1.35 [0.83 2.21] | p=1.00 | 0 | 532 | 1 | VA Neurology Section, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | 0.87 [0.78 0.97] | p=0.04 | 0 | 17026 | 6 | WHO clofibrate, CDP Clofibrate, Scottish, Newcastle, VA Neurology Section, Hanefeld, | | Coronary death and non fatal MI | no data | | Coronary death | 0.86 [0.74 0.99] | p=0.04 | 0 | 16523 | 8 | WHO clofibrate, CDP Clofibrate, Scottish, Newcastle, Harrold, Begg, VA Neurology Section, Cullen, | | cardiac death | 0.87 [0.75 1.00] | p=1.00 | 0 | 16523 | 8 | WHO clofibrate, CDP Clofibrate, Scottish, Newcastle, Harrold, Begg, VA Neurology Section, Cullen, | | MACE | no data | | Non fatal MI | 0.82 [0.71 0.94] | p=0.04 | 0 | 15733 | 4 | WHO clofibrate, CDP Clofibrate, Scottish, Newcastle, | | All cause death | 1.00 [0.89 1.12] | p=1.00 | 0 | 16618 | 9 | WHO clofibrate, CDP Clofibrate, Scottish, Newcastle, Harrold, Begg, Acheson, VA Neurology Section, Cullen, | | non cardiovascular death | 1.42 [1.18 1.72] | p=0.04 | 0 | 15733 | 4 | WHO clofibrate, CDP Clofibrate, Scottish, Newcastle, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 1.29 [0.94 1.78] | p=1.00 | 0 | 14519 | 2 | WHO clofibrate, CDP Clofibrate, | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| WHO clofibrate, 1978 | clofibrate 1.6 g daily | olive oil | primary prevention, Hommes, de 30 à 59 ans | | CDP Clofibrate, 1975 | clofibrate 1.8 mg/d | placebo | men, 30-64 y | | Scottish, 1971 | clofibrate 1.6-2 g daily | placebo | Hommes et femmes, de 40 à 69 ans | | Newcastle, 1971 | clofibrate 1.5-2 g daily | placebo | Hommes et femmes < 65 ans
| | Harrold, 1969 | clofibrate | placebo | diabetic retinopathy | | Begg, 1971 | clofibrate | placebo | peripheral arteriopathy | | Acheson, 1972 | clofibrate | placebo | cerebral vascular disease | | VA Neurology Section, 1974 | clofibrate | placebo | treatment of cerebrovascular disease
| | Cullen, 1974 | clofibrate | placebo |
| | Hanefeld, 1991 | clofibric acid 1.6 g/day | placebo | newly diagnosed middle-aged (30- to 55-yr-old) patients with non-insulin-dependent diabetes mellitus |
| |
| Etofibrate | cardiovascular prevention, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | no data | | MACE | no data | | Non fatal MI | no data | | All cause death | no data | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Emmerich, 2009 | etofibrate 1g/j | placebo | patients with type 2 diabetes mellitus and concomitant diabetic retinopathy |
| |
| Fenofibrate | cardiovascular prevention, in all type of patients | vs placebo | Venous thromboembolism by 50% suggested Non fatal MI by 24% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Venous thromboembolism | 1.50 [1.13 2.00] | p=0.04 | 0 | 9795 | 1 | FIELD, | | cardiovascular events | 0.90 [0.80 1.01] | p=1.00 | 0 | 9795 | 1 | FIELD, | | Cardiovascular death | 1.10 [0.86 1.41] | p=1.00 | 0 | 9795 | 1 | FIELD, | | stroke (fatal and non fatal) | 0.90 [0.73 1.12] | p=1.00 | 0 | 9795 | 1 | FIELD, | | Coronary event | 0.88 [0.74 1.03] | p=1.00 | 0 | 10213 | 2 | FIELD, DAIS, | | Coronary death and non fatal MI | 0.89 [0.75 1.06] | p=1.00 | 0 | 9795 | 1 | FIELD, | | Coronary death | 1.18 [0.90 1.57] | p=1.00 | 0 | 9795 | 1 | FIELD, | | cardiac death | 1.16 [0.88 1.52] | p=1.00 | 0 | 10213 | 2 | FIELD, DAIS, | | MACE | no data | | Non fatal MI | 0.76 [0.62 0.94] | p=0.04 | 0 | 9795 | 1 | FIELD, | | All cause death | 1.09 [0.94 1.27] | p=1.00 | 0 | 10213 | 2 | FIELD, DAIS, | | non cardiovascular death | 0.51 [0.09 2.81] | p=1.00 | 0 | 418 | 1 | DAIS, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 1.14 [0.91 1.42] | p=1.00 | 0 | 9795 | 1 | FIELD, | | Rhabdomyolysis | 3.00 [0.31 28.88] | p=1.00 | 0 | 9795 | 1 | FIELD, | | Myopathy | 2.00 [0.18 22.09] | p=1.00 | 0 | 9795 | 1 | FIELD, | | Cancer | no data | | Adverse events | 1.58 [0.95 2.65] | p=1.00 | 0 | 9795 | 1 | FIELD, |
| Trial | Studied treatment | Control | Patients |
|---|
| FIELD, 2005 | fenofibrate 200mg/d | Placebo | participants aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry | | DAIS, 2001 | fenofibrate 200 mg/day | placebo | men and women with type 2 diabetes and coronary atherosclerosis |
| |
| Fenofibrate | | vs placebo (on top simvastatine) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.93 [0.79 1.11] | p=1.00 | 0 | 5518 | 1 | ACCORD lipid, | | Cardiovascular death | 0.86 [0.66 1.14] | p=1.00 | 0 | 5518 | 1 | ACCORD lipid, | | stroke (fatal and non fatal) | 1.06 [0.71 1.57] | p=1.00 | 0 | 5518 | 1 | ACCORD lipid, | | Coronary event | 0.94 [0.80 1.10] | p=1.00 | 0 | 5518 | 1 | ACCORD lipid, | | retinopathy | no data | | vision loss | no data | | All cause death | 0.91 [0.75 1.12] | p=1.00 | 0 | 5518 | 1 | ACCORD lipid, |
| Trial | Studied treatment | Control | Patients |
|---|
| ACCORD lipid, 2010 | fenofibrate on top simvastatin | placebo (on top simvastatine) | high-risk patients with type 2 diabetes |
| |
| Gemfibrozil | cardiovascular prevention, in all type of patients | vs placebo | cardiovascular events by 22% suggested Coronary event by 23% suggested Non fatal MI by 25% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.78 [0.65 0.94] | p=0.04 | 0 | 2531 | 1 | VA-HIT, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.76 [0.54 1.09] | p=1.00 | 0 | 2531 | 1 | VA-HIT, | | Coronary event | 0.77 [0.65 0.91] | p=0.04 | 0 | 7007 | 3 | VA-HIT, Helsinki (HHS), LOCAT, | | Coronary death and non fatal MI | no data | | Coronary death | 0.78 [0.60 1.02] | p=1.00 | 0 | 6612 | 2 | VA-HIT, Helsinki (HHS), | | cardiac death | 0.85 [0.66 1.10] | p=1.00 | 0 | 7240 | 3 | VA-HIT, Helsinki (HHS), HHS (Frick)(secondary prev subgroup), | | MACE | no data | | Non fatal MI | 0.75 [0.61 0.91] | p=0.04 | 0 | 6612 | 2 | VA-HIT, Helsinki (HHS), | | All cause death | 0.96 [0.80 1.15] | p=1.00 | 0 | 7240 | 3 | VA-HIT, Helsinki (HHS), HHS (Frick)(secondary prev subgroup), | | non cardiovascular death | 1.11 [0.86 1.43] | p=1.00 | 0 | 7240 | 3 | VA-HIT, Helsinki (HHS), HHS (Frick)(secondary prev subgroup), | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 0.90 [0.63 1.31] | p=1.00 | 0 | 6612 | 2 | VA-HIT, Helsinki (HHS), | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | 0.91 [0.70 1.17] | p=1.00 | 0 | 2531 | 1 | VA-HIT, | | Adverse events | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| VA-HIT, 1999 | gemfibrozil 1.2g daily | placebo | men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less | | Helsinki (HHS), 1987 | gemfibrozil 1,2 g/d | placebo | asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter [5.2 mmol per liter] | | HHS (Frick)(secondary prev subgroup), 1993 | gemfibrozil 600 mg twice daily | placebo | individuals who exhibited symptoms and signs of possible coronary heart disease | | LOCAT, 1997 | gemfibrozil 1200 mg/d | placebo | post-coronary bypass men, who had an HDL cholesterol concentration < or = 1.1 mmol/L and LDL cholesterol < or = 4.5 mmol/L |
| |
| Niacin | cardiovascular prevention, in all type of patients | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | 1.05 [0.50 2.21] | p=1.00 | 0 | 220 | 1 | VA drugs, | | MACE | no data | | Non fatal MI | no data | | All cause death | 1.03 [0.51 2.08] | p=1.00 | 0 | 220 | 1 | VA drugs, | | non cardiovascular death | 0.93 [0.17 5.19] | p=1.00 | 0 | 220 | 1 | VA drugs, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| VA drugs, 1968 | niacin | | |
| |
| Niacin | | vs placebo | Coronary event by 15% suggested Non fatal MI by 26% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | 0.85 [0.73 1.00] | p=0.04 | 0 | 3908 | 1 | CDP niacin, | | Coronary death and non fatal MI | no data | | Coronary death | 0.95 [0.79 1.13] | p=1.00 | 0 | 3908 | 1 | CDP niacin, | | cardiac death | no data | | MACE | no data | | Non fatal MI | 0.74 [0.59 0.92] | p=0.04 | 0 | 3908 | 1 | CDP niacin, | | All cause death | 0.96 [0.82 1.13] | p=1.00 | 0 | 3908 | 1 | CDP niacin, | | non cardiovascular death | 1.15 [0.76 1.72] | p=1.00 | 0 | 3908 | 1 | CDP niacin, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 0.93 [0.43 2.02] | p=1.00 | 0 | 3908 | 1 | CDP niacin, | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| CDP niacin, 1975 | niacin 3 mg/d | placebo | Hommes, de 30 à 64 ans |
| |
| Niacin | | vs placebo (on top statin) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.96 [0.90 1.03] | p=1.00 | 0 | 29414 | 4 | AIM-HIGH, HPS 2-Thrive, ARBITER 2, HATS, | | Cardiovascular death | 1.09 [0.95 1.24] | p=1.00 | 0 | 26000 | 3 | HPS 2-Thrive, ARBITER 2, HATS, | | stroke (fatal and non fatal) | 1.02 [0.90 1.15] | p=1.00 | 0 | 29330 | 4 | AIM-HIGH, HPS 2-Thrive, ARBITER 2, HATS, | | Coronary event | 0.97 [0.88 1.07] | p=1.00 | 0 | 29325 | 4 | AIM-HIGH, HPS 2-Thrive, ARBITER 2, HATS, | | All cause death | 1.09 [0.98 1.21] | p=1.00 | 0 | 25833 | 2 | HPS 2-Thrive, HATS, |
| Trial | Studied treatment | Control | Patients |
|---|
| AIM-HIGH, 2011 | high-dose, extended-release niacin in gradually increasing doses up to 2000 mg daily (+ simvastatin) | placebo | patients with a history of cardiovascular disease, high triglycerides, and low levels of HDL cholesterol | | HPS 2-Thrive, | 2 g of extended-release niacin and 40 mg of laropiprant | placebo | patients with vascular disease | | Oxford Niaspan Study, 2009 | niacin 2g daily (added to statin therapy) | placebo (statins alone) | patients with low HDL-C (<40 mg/dl) and either a type 2 diabetes with coronary heart disease or a carotid/peripheral atherosclerosis | | ARBITER 2, 2009 | long-acting niacin target dose of 1 g/day (added to statin therapy) | placebo | patients with known coronary artery disease and well controlled on statin therapy | | HATS, 2001 | simvastatin plus niacin | placebo | patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels |
| |
| Niacin | | vs ezetimibe | cardiovascular events by 2849% suggested Coronary event by 79% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 29.49 [15.39 56.51] | p=0.04 | 0 | 363 | 1 | ARBITER 6-HALTS (niacin vs ezetimibe), | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | 0.21 [0.04 0.98] | p=0.04 | 0 | 363 | 1 | ARBITER 6-HALTS (niacin vs ezetimibe), | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| ARBITER 6-HALTS (niacin vs ezetimibe), 2009 | extended-release niacin 1 g/d, titrated to max tolerable dose up to 2 g/d (HDL-focused strategy) | ezetimibe 10 mg/d (LDL-focused strategy) | patients with known coronary or vascular disease or coronary risk equivalents |
| |
